Results 211 to 220 of about 793,336 (333)

Central Nervous System axonal regeneration by spatially targeted drug combinations [PDF]

, 2017
Mustafa M. Siddiq, Nicholas P. Johnson, Yana Zorina, Arjun S. Yadaw, Carlos A. Toro, Jens Hansen, Vera Rabinovich, Sarah M. Gregorich, Yuguang Xiong, Rosa E. Tolentino, Sari S. Hannila, Ehud Kaplan, Robert D. Blitzer, Marie T. Filbin, Christopher Cardozo, Christopher L. Passaglia, Ravi Iyengar   +16 more
openalex   +1 more source

Supplemental Text, Supplemental Figures, and Supplemental Tables from Cell Line–Specific Network Models of ER⁺ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

, 2023
Jorge Gómez Tejeda Zañudo, Pingping Mao, Clara Alcon, Kailey J. Kowalski, Gabriela N. Johnson, Guotai Xu, José Baselga, Maurizio Scaltriti, Anthony Letai, Joan Montero, Réka Albert, Nikhil Wagle   +11 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Statistical innovations in clinical trial design with a focus on drug combinations, factorials, and other multiple therapy issues. [PDF]

J Prev Alzheimers Dis
Berry DA.
europepmc   +1 more source

In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against ClinicalScedosporium prolificansIsolates

, 2002
Joseph Meletiadis, Johan W. Mouton, Jacques F. Meis, Paul E. Verweij   +3 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Efficacy and safety of drug combinations for chronic pelvic pain: a systematic review. [PDF]

Pain Rep
Mohiuddin M, Park R, Wesselmann U, Pukall C, Jarvi K, Nickel JC, Doiron RC, Halliday S, Gilron I.   +8 more
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia. [PDF]

Cancer Res
Chen Y, He L, Ianevski A, Nader K, Ruokoranta T, Linnavirta N, Miettinen JJ, Vähä-Koskela M, Vänttinen I, Kuusanmäki H, Kontro M, Porkka K, Wennerberg K, Heckman CA, Giri AK, Aittokallio T.   +15 more
europepmc   +1 more source